<?xml version="1.0" encoding="UTF-8"?>
<p>For some pathogens, clinical trials in infected patients are not possible or desirable. In the case of inhalational anthrax, raxibacumab has been approved using the FDA “Animal Rule” [
 <xref rid="pntd.0007860.ref033" ref-type="bibr">33</xref>]. This provides a route forward in disease areas in which trials with infected human patients are not possible or not ethical.
</p>
